Barclays PLC Gemini Therapeutics, Inc. Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding GMTX
# of Institutions
1Shares Held
2.44MCall Options Held
0Put Options Held
0About Gemini Therapeutics, Inc.
- Ticker GMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,244,500
- Market Cap $1.05B
- Description
- Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...